Your browser doesn't support javascript.
loading
Sinoatrial Node Dose Is Associated With Worse Survival in Patients Undergoing Definitive Stereotactic Body Radiation Therapy for Central Lung Cancers.
Iovoli, Austin J; Yu, Han; Advani, Pragati G; Turecki, Lauren; Malhotra, Harish K; Malik, Nadia K; Fung-Kee-Fung, Simon; Singh, Anurag K; Farrugia, Mark K.
Afiliação
  • Iovoli AJ; Departments of Radiation Medicine.
  • Yu H; Biostatistics & Bioinformatics.
  • Advani PG; Internal Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Turecki L; Jacobs School of Medicine and Biomedical Sciences University at Buffalo, Buffalo, New York.
  • Malhotra HK; Departments of Radiation Medicine.
  • Malik NK; Departments of Radiation Medicine.
  • Fung-Kee-Fung S; Departments of Radiation Medicine.
  • Singh AK; Departments of Radiation Medicine.
  • Farrugia MK; Departments of Radiation Medicine. Electronic address: Mark.Farrugia@roswellpark.org.
Pract Radiat Oncol ; 14(1): e40-e47, 2024.
Article em En | MEDLINE | ID: mdl-37804882
ABSTRACT

PURPOSE:

Our purpose was to evaluate the clinical consequences of sinoatrial node (SAN) and atrioventricular node (AVN) irradiation in patients undergoing stereotactic body radiation therapy (SBRT) for central non-small cell lung cancer (NSCLC) tumors. METHODS AND MATERIALS A single-institutional retrospective review of patients with primary NSCLC undergoing definitive SBRT for centrally located thoracic tumors from February 2007 to December 2021 was performed. The SAN and AVN were contoured in accordance with a published contouring atlas, and the maximum dose (Dmax) and mean dose (Dmean) for each structure were calculated. Sequential log rank testing between the 50th and 90th percentiles was used to identify potential cutoff values for the corresponding dosimetric parameters and overall survival.

RESULTS:

Among 93 eligible patients, the median age was 72.5 years (IQR, 66.6-78.3), and median follow-up was 32.4 months (IQR, 13.0-49.6). The median SAN Dmax and Dmean were 95 cGy (range, 9-5394) and 58 cGy (range, 7-3168), respectively. The median AVN Dmax and Dmean were 45 cGy (range, 4-2121) and 34 cGy (range, 3-1667), respectively. Candidate cutoff values for SAN Dmax and Dmean were 1309 and 836 cGy, respectively. No associations between AVN parameters and survival outcomes were identified. Upon multivariate Cox regression, the SAN Dmax cutoff (hazard ratio [HR], 2.03 [1.09-3.79]; P = .026) and SAN Dmean cutoff (HR, 2.22 [1.20-4.12]; P = .011) were significantly associated with overall survival. For noncancer-associated survival, the SAN Dmax cutoff trended toward significance (HR, 2.02 [0.89-4.57]; P = .092), and the SAN Dmean cutoff remained significantly associated (HR, 2.34 [1.05-5.18]; P = .037).

CONCLUSIONS:

For patients undergoing SBRT for NSCLC, SAN Dmax and Dmean were significantly associated with worse overall survival using cut-off values of 1309 and 836 cGy, respectively. Further studies examining the effect of SAN irradiation during SBRT are warranted.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Radiocirurgia / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Risk_factors_studies Limite: Aged / Humans Idioma: En Revista: Pract Radiat Oncol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Radiocirurgia / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Risk_factors_studies Limite: Aged / Humans Idioma: En Revista: Pract Radiat Oncol Ano de publicação: 2024 Tipo de documento: Article